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Abstract 
Background: Carbapenem resistance is a major and a future public health problem 
globally. It occurs mainly among Gram-negative bacteria.  Meropenem is the recently 
marketed carbapenem drug in Yemen. However, recent emergence of carbapenem-
resistant isolates has become a major healthcare concern. 
Objectives: The current study was designed to estimate the prevalence of meropenem 
resistance among hospitalised patients in Sana'a, Yemen. 
Methods: The study was performed at a local hospital in Sana’a, Yemen. The records 
of Meropenem susceptibility were taken for hospitalised patients. A total of 443 
Meropenem susceptibility samples were collected from August, 2017 to July, 2018. 
The meropenem susceptibility was studied against several isolated pathogens. 
Results: Out of 443 study sample, 316 (71.3%) were meropenem sensitive isolates and 
25.3% of samples were resistant. The Escherichia coli isolates were observed in 27.5% of 
sample, followed by Pseudomonas aeruginosa (19.6%). 36.4% of total meropenem sensitive 
isolates (115/316) were Escherichia coli. In addition, 94.3% (115/122) of Escherichia coli 
isolates were meropenem sensitive. However, the Klebsiella species had higher meropenem 
resistance than other pathogens (30/112; 26.8%). Moreover, 89.7% (26/29) of Acinetobacter 
species isolates were meropenem resistant. 82.4% (42/51) of Klebsiella pneumonia isolates 
were meropenem sensitive and 32.2% (28/87) of Pseudomonas aeruginosa were meropenem 
resistance. In the present study, 34.5% (109/316) of meropenem sensitive isolates were from 
blood cultures, followed by sputum cultures (23.7%; 75/316). However, 58% (65/112) of 
sputum culture isolates were meropenem resistance. 
Conclusion:  This study concluded that the percentage of resistance to meropenem was high 
(25.3%) and cannot be neglected. Continued surveillance to closely monitor trends as well as 
infection control and antibiotic stewardship activities are necessary to preserve treatment 
options. A more careful monitoring for use of broad-spectrum antibiotics should be instituted. 
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Introduction: 
Carbapenems are the most effective drugs against most bacteria. Bacterial resistance 
continues to increase, and drug researchers and manufacturing industries are not 
producing new drugs to replace the existing antimicrobials against which resistance 
has developed. The economic impact related to antimicrobial resistance was expected 
to cost over $105 billion annually worldwide
 [1]
. Recently, occurrence of antibiotics 
resistance is quickly changing. Many deaths have demonstrated as a consequence of 
this in Europe. About 25,000 of subjects may die each year as a result of infection 
related to antibiotics resistance 
[2]
. Globally, the resistance reports of bacterial 
infections are alarming. Carbapenems have a broad spectrum and a unique structure 
against most β lactamases such as metallo-β-lactamase (MBL) and extended spectrum 
β-lactamases [3]. The carbapenem resistance has been increasing world-wide over the 
last years with local differences in prevalence and mechanisms of resistance 
[4]
. The 
emergence and spread of resistance to these antibiotics constitute a major public 
health problem 
[5]
.  In addition, carbapenems are the effective drugs for treatment of 
multidrug-resistance (MDR) isolates. However, the carbapenem-resistant among these 
isolates has recently increasing and become a worldwide alarm concern 
[6]
. Because of 
MDR, there are few alternatives for treatment of patients with serious infections 
[5]
.  
Meropenem is the recently marketed carbapenem drug in Yemen. Carbapenem 
resistance is a major public health problem and in progress globally. Thus, the aim of 
 current study was to estimate the prevalence of meropenem resistance among 
hospitalised patients in Sana'a, Yemen. 
Methods: The study was performed at a local hospital in Sana’a, Yemen. The records 
of Meropenem susceptibility were taken for hospitalised patients. Meropenem 
susceptibility samples were collected from August, 2017 to July, 2018. The 
meropenem susceptibility was studied against several isolates. Full ethical clearance 
was obtained from the qualified authorities who approved the study design. All data 
were analyzed using SPSS Statistics 21. 
Results: 
According to the present study, the mean age of study sample (n=443) was 45.8 year 
(with SD ± 20.66 year) and ranged between 1 and 92 years. Out of 443 samples, 311 
(71.3%) were meropenem sensitive isolates and only one four of samples (25.3%) 
were resistant.  Also (67.3%) of total patients were males and (32.7%) were female. 
Among 443 of patients, (39.3%) was aged between 41- 60 years and 24.4% up to 16 
years. The Escherichia coli was observed in 27.5% of sample isolates, the next type 
of bacteria was Pseudomonas aeruginosa (19.6%). From the study findings, 32.3% of 
sample was isolated from sputum cultures and 31.2% from blood cultures (table 1). 
Table 1: Distribution of Study variables 
variable Level of variable Frequency Percent 
Culture 
Result 
S 316 71.3 
I 15 3.4 
R 112 25.3 
Total 443 100.0 
 
Sex 
 
M 298 67.3 
F 145 32.7 
Total 443 100.0 
 
Age order 
Less 20 66 14.9 
21-40 95 21.4 
41-60 174 39.3 
Up to60 108 24.4 
Total 443 100.0 
 
 
 
 
 
 
Type of  
bacteria 
Escherichia coli 122 27.5 
Proteus Spp 5 1.1 
Pseudomonas aeruginosa 87 19.6 
Coagulase negative Staphylococci 55 12.4 
Staphylococcus aureus 23 5.2 
Klebsiella Spp 42 9.5 
Acinetobacter species 29 6.5 
Klebsiella pneumoniae 51 11.5 
Streptococcus spp. 10 2.3 
Enterobacter Spp 9 2.0 
Serratia Spp 1 0.2 
Enterococcus Spp 4 0.9 
Proteus vulgaris 2 0.5 
Haemophilus Spp 2 0.5 
Alpha Hemolytic Streptococcus 1 0.2 
Total 443 100.0 
Type of  
sample 
Urine Culture 32 7.2 
Blood Culture 138 31.2 
 Wound Swab  For Culture 41 9.3 
Pus For Culture & Sensitivity 52 11.7 
Sputum Culture 143 32.3 
Aspirated Fluid Culture 12 2.7 
General swab for Culture 12 2.7 
Cerepro Spinal Fluid ( CSF ) C/S 7 1.6 
Pleural Fluid For Culture & 
Sensitivity 
4 0.9 
High Vaginal Swab  (HVS) C/S 1 0.2 
Ascitic fluid C/S and sensitivity 1 0.2 
Total 443 100.0 
There was not statistically significant difference between culture results with both sex 
and age group (P-value = 0.1 and 0.2 respectively). However, 40.2% of females had 
meropenem resistant and 48.2% of samples resistant were aged 41-60 years (table 2).  
Table 2: Distribution of age group and sex according to Culture results  
 
Variable 
Culture results  
Total 
 
P-value 
S I   R 
Sex 
M 219 12 67 298  
0.1 
 
F 97 3 45 145 
Total 316 15 112 443 
Age group 
Less 20 51 3 12 66  
0.2 
21-40 70 1 24 95 
41-60 112 8 54 174 
Up to60 83 3 22 108 
Total 316 15 112 443 
Results in table 3 indicated that the relationship between bacteria type and culture 
results was statistically significant (P-value = 0.001). Also the study findings reported 
that 36.4% of total meropenem sensitive isolates (71.3%) were Escherichia coli, 
followed by Pseudomonas aeruginosa (17.7%). However, the Klebsiella Spp. was the 
higher resistant type of bacteria (26.8%). 
Table 3: Distribution of bacteria type according to culture results 
 
variable 
Culture results  
Total 
 
P-
value 
S I R 
Bacteria 
type 
Escherichia coli 115 3 4 122  
 
 
0.001 
 
 
 
Proteus Spp 5 0 0 5 
Pseudomonas aeruginosa 56 3 28 87 
Coagulase negative Staphylococci 38 5 12 55 
Staphylococcus aureus 21 0 2 23 
Klebsiella Spp 12 0 30 42 
Acinetobacter species 2 1 26 29 
Klebsiella pneumoniae 42 2 7 51 
Streptococcus spp. 10 0 0 10 
Enterobacter Spp 8 0 1 9 
Serratia Spp 1 0 0 1 
Enterococcus Spp 1 1 2 4 
Proteus vulgaris 2 0 0 2 
Haemophilus Spp 2 0 0 2 
 
Alpha Hemolytic Streptococcus 1 0 0 1 
Total 316 15 112 443 
The relationship between culture results and sample type was analyzed in the table 4.  
Results in this table showed that there was high significantly relationship (P-value = 
0.001).  Also 34.49% of meropenem sensitive isolates were from blood cultures, 
followed by sputum cultures (23.7%). However, 58% of isolates from sputum cultures 
were meropenem resistant.  
Table 4: Distribution of culture results according to sample type   
 
variable 
Culture results  
Total 
 
P-value S I R 
Sample 
type 
Urine Culture 24 1 7 32  
 
 
 
 
 
 
0.001 
 
 
Blood Culture 109 7 22 138 
Wound Swab  For Culture 33 1 7 41 
Pus For Culture & Sensitivity 47 2 3 52 
Sputum Culture 75 3 65 143 
Aspirated Fluid Culture 10 1 1 12 
General swab for Culture 7 0 5 12 
CSF C/S 7 0 0 7 
Pleural Fluid For Culture & 
Sensitivity 
3 0 1 4 
High Vaginal Swab C/S 1 0 0 1 
Ascitic fluid c/s and sensitivity 0 0 1 1 
Total 316 15 112 443 
Discussion: 
In this study, the prevalence of meropenem resistance among isolates was 25.3%. It 
was similar to a study by Mulla S et al who reported 30% meropenem resistance
 [7]
 
and to a study by Mahajan G et al. [8] who found 31.81% meropenem resistance. 
Some studies recorded lower level of carbapenem resistance. Shivesh P et al. 
[9]
 
reported 15 % and Shashikala et al. 
[10]
 found 10.9% carbapenem resistance in their 
respective studies. In a study by Sachinkumar Wankhede et al. 
[11]
 found 19.40% 
carbapenem resistant. Resistance to carbapenem in this study is low compared to 
studies from India. In a study in New Delhi by Bijayini Behera et al. [12] carbapenem 
resistance was found to be 69%, which much on the higher side. 
Our finding was agreed with the study conducted by Basher et al.
 [13]
, 2016 in 
Khartoum state; she found that 25.6% of clinical isolates were resistant to Meropenem 
antibiotic; also similar to study conducted by Khanda Abdallatif Anwar in Iraq, 2011 
who reported that 22% of the isolates were meropenem resistant
 [14]
. However, less 
than study conducted by Noyal M et al.
 [15]
 which found that 43% of the isolates were 
meropenem resistant. 
In the present study, maximum number of meropenem sensitive isolates was from 
blood samples 34.5% (109/316) followed by sputum samples 23.7% (75/316). 
However, 58% (65/112) of sputum samples isolates were meropenem resistance. 
Nagaraj S et al 
[16]
 reported different findings where they observed that the 
carbapenem-resistant organisms were isolated mainly from urine samples up to 42%, 
followed by wound discharge 18% and respiratory secretions 16%. Sputum samples 
(n=143) and blood samples (n=138) were the most frequent samples received during 
our study and in most of the studies analysed. The reason for this could be respiratory 
infection, being the most common hospital-acquired infection.  
 In our study, the resistant of Pseudomonas species was in agreement with study 
findings in Sudan 20% 
[13]
. According to the study findings, 94.3% (115/122) of 
Escherichia coli isolates were meropenem sensitive. This was disagreed with a study 
done by Sharif A et al.
 [17]
 in Nigeria who reported that E. coli was the most resistant 
organism. According to a study conducted by Noyal M et al.
 [18]
, acinetobacter was 
the most resistant organism. Similarly, 89.7% (n=26/29) of acinetobacter species 
isolates were meropenem resistant in the current study. Carbapenem is the last resort 
for treatment of life threatening infections in hospital. Judicious use and constant 
monitoring are essential to check the spread of imipenem/ meropenem resistant in 
hospitals and its subsequent spread in the community. The use of carbapenem for the 
treatment of infection should be reserved for situations where the infection is 
polymicrobial or for isolates resistant to other antibiotics. Antibiotic resistance is 
increasing at an alarming rate, leading to increased morbidity, mortality and treatment 
costs. A key factor in the development of antibiotic resistance is the inappropriate use 
of antibiotics. Also attention by the hospital infection control team is essential to 
implement stringent preventive measures to contain the spread of the infection and 
promote the judicious use of antimicrobial agents. 
Conclusion: 
This study concluded that the percentage of resistance to Carbapenem antibiotics was 
high (25.3%) and cannot be neglected. The most meropenem resistant organisms were 
Acinetobacter species, Klebsiella species, and Pseudomonas aureginosa. Despite 
efforts to control carbapenem resistance, a definite solution to the problem is still far 
from achievement. 
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